Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin vs Active Control in Relapsed/Refractory ALL
CTR20140789Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Started Apr 2017; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20140789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140789.